Alexion Pharmaceuticals (NASDAQ:ALXN) Should Follow 2010 with Another Strong year

Citing the continued strong growth in sales of Soliris and the results of aHUS, Needham believes Alexion Pharmaceuticals (NASDAQ:ALXN) should be considered a stock of interest in 2011.

Needham said, "The highlights of the 2010 Season of Biotech (Sep-Dec) for Alexion Pharmaceuticals were the continued strong growth of Soliris sales as well as the impressive results in aHUS that may provide a significant label expansion opportunity for Soliris. We view ALXN as a stock of added interest in 2011...We believe that ALXN stock is of added interest to investors focusing on mid-cap, revenue-generating biotech names."

Needham & Company reiterates a "Buy" rating on Alexion Pharmaceuticals, which closed Wednesday at $82.76, gaining $1.29, or 1.58 percent.